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Optical coherence tomography (OCT) provides real-time, objective, in-vivo, optical cross-
sectional representations of the retina and optic nerve. Recent innovations in image acquisition, 
including the incorporation of Fourier/spectral-domain detection, have improved imaging speed, 
sensitivity and resolution. Still, there remain specific structures within ocular OCT images, such 
as retinal ganglion cells (RGCs), which are of clinical interest but consistently have low contrast. 
This makes it difficult to differentiate between surrounding layers and structures.  
The objectives of this project were: 1. To establish a reliable method for OCT imaging of 
the healthy and diseased mouse eye in order to provide a platform for testing the utility of OCT 
contrast agents for ocular imaging, 2. To develop antibody-conjugated gold nanoparticles 
suitable for targeting specific structures and enhancing OCT image contrast in the mouse eye, 
and 3. To examine the localized contrast-enhancing ability and biocompatibility of gold 
nanoparticle contrast agents in-vivo. Our organizing hypotheses were that nanoparticles could 
improve contrast by modulating the intensity of backscattered light detected by OCT and that 
they could be directed to ocular structures of interest using antibodies specific to cellular 
markers.  
A reproducible method for imaging the mouse retina and quantifying retinal thickness 
was developed and this technique was then applied to a mouse model for retinal ganglion cell 
loss, optic nerve crush. Gold nanorods were designed specifically to augment the backscattering 
OCT signal at the same wavelengths of light used in current ophthalmic OCT imaging schemes 
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(resonant wavelength λ = 840 nm). Anti-CD90.1 (Thy1.1) antibodies were conjugated to the 
gold nanorods and a protocol for characterization of the success of antibody conjugation was 
developed. Upon injection, the gold nanorods were found to remain in the vitreous post-
injection, with many consumed by an early inflammatory response and only very few reaching 
the internal limiting membrane and passing into the retina. Our findings suggest that, while gold 
nanorods are able to locally increase OCT signal intensity in the vitreous, their utility in the 
retina may be limited. 
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1.0  INTRODUCTION 
Optical coherence tomography (OCT) is a noncontact imaging modality that provides cross-
sectional images of biological structures, in-vivo and non-invasively, by detecting light 
backscattered from tissue. In ophthalmology, OCT is primarily used to image the retina and optic 
nerve, in order to detect and monitor a variety of retinal diseases and optic neuropathies. The use 
of OCT has increased in recent years, due to software and hardware improvements1-4 that allow 
rapid collection of high-resolution, three-dimensional (3D) datasets, and clinical studies 
confirming the reproducibility5-11 and disease-discriminating capability12-17 of measurements. 
OCT is now becoming accepted as a reliable tool for clinicians assessing ocular structure. 
Contrast agents are substances designed to alter the detected signal of a biological image 
in a way that allows the region containing the agent to be discernible. For example, in X-ray 
imaging, high atomic number elements such as iodine are routinely used to improve delineation 
of blood vessels and organs by the absorption of incident X-rays.18 Medical imaging techniques 
such as X-ray, magnetic resonance imaging (MRI), computed tomography and ultrasound each 
may be augmented by contrast agents approved by the Federal Drug Administration  (FDA).18, 19  
To date, there are no FDA-approved contrast agents for imaging with OCT. The 
existence of such an agent would have the potential to improve delineation of ocular structures 
that normally exhibit minimal backscatter and thus have low contrast within optical cross-
sections.  Given the nature of OCT detection, the presence of scattering media at the level of 
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low-scattering regions of interest may provide the contrast needed to isolate those structures. 
Gold nanoparticles can be nanoengineered to be highly backscattering at the near infrared (NIR) 
wavelengths used in OCT imaging.20, 21 Moreover, their surfaces can be modified to allow 
antibody conjugation.22, 23 These properties make gold nanoparticles a natural choice for targeted 
contrast within OCT images. 
The central hypotheses of this dissertation are that nanoparticles can improve contrast by 
modulating the intensity of backscattered light detected by OCT and that they could be directed 
to ocular structures of interest using antibodies specific to cellular markers. 
1.1 OPTICAL COHERENCE TOMOGRAPHY 
OCT is based on the principles of interferometric detection, in which light echoes backscattered 
from the retina interfere with light that has traveled to a reference mirror at a known time delay. 
Echoes from a single point on the retina represent an axial scan (A-scan), and optical cross-
sections (B-scans) are obtained by scanning the OCT beam in the transverse direction. 
The center wavelength of the light source used for OCT imaging dictates depth of 
penetration into the retina, and the bandwidth of the light source governs axial resolution (∆z) as 
follows: 
∆z = lc/2 = [(2ln2)/(πn)]* [(λ2/∆λFWHM)] 
where lc is the coherence length, λ is the center wavelength, and ∆λFWHM is the full width at half-
maximum of the applied light, and n is the refractive index of the sample.24 Traditionally, center 
wavelengths of ~840 nm and bandwidths of ~25 nm have been used for ocular imaging to 
provide structural details of the inner retina at a resolution of ~8-10 µm. Recently, light sources 
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with longer center wavelengths (1050 nm, 1310 nm) have been employed in addition to the 830 
nm sources for enhanced depth penetration (e.g., lamina cribrosa and choroidal imaging) and 
improved signal quality in subjects with lens opacities.25-29 In addition, broader bandwidth light 
sources (∆λ=100-200nm) have been integrated into OCT systems to improve axial resolution to 
1-3µm,1, 30, 31 and high-speed scanning (60-100x faster than the first-generation OCT system) is 
now possible using Fourier/spectral domain (SD-) OCT detection.2, 3, 32-35 
Fourier-domain detection, which consists of both spectral-domain (SD-OCT; Figure 1) 
and swept-source (SS-OCT) methods, does not require a moving reference mirror to collect A-
scan profiles. Instead, frequency information from all depths at a given point on the retina is 
acquired simultaneously by a CCD camera and spectrometer (SD-OCT), or by sweeping through 
a range of frequencies (SS-OCT); frequency data are subsequently translated into intensity 
information using a Fourier transform. Speeds of up to 312.5 kHz have been accomplished with 
SD-OCT36 and 249 kHz with SS-OCT.29 
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Figure 1. Schematic diagram of our spectral-domain OCT system. Light from a broadband 
superluminescent diode is split, with 80% going to the eye and 20% to a stationary reference mirror. The light 
recombines and an interference pattern is detected using a spectrometer and charge-coupled device (CCD) camera, 
and Fourier-transformed to obtain a reflectivity profile. Red arrows indicate the optical path. ∆λFWHM - full width at 
half-maximum of the applied light; λ - center wavelength. 
 
Two-dimensional collection of intensity information involves transverse scanning across 
a retinal region of interest to gradually acquire a series of neighboring A-scans. Taken together, 
these A-scans comprise B-scans or optical cross-sections of tissue (Figure 2). 
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Figure 2. Two-dimensional SD-OCT cross-sectional scan (B-scan) through the macula of a human subject. 
The vertical white line denotes the location of the single A-scan intensity profile shown on the right. This macular 
cross-section scan consisted of 1000 A-scans, 1024 pixels in depth (6 mm x 2 mm). 
 
In three-dimensional (3D) OCT, the collection of intensity information involves the 
acquisition of several neighboring B-scans. Volumes of data consist of multiple A-scans per B-
scan and multiple B-scans per 3D volume. Once a 3D volume has been acquired, an OCT enface 
(OCT fundus) image can be created by integrating intensity information along the axial direction, 
such that one summed A-scan represents a single pixel in the OCT fundus image (Figure 3). 
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Figure 3. SD-OCT fundus image of the optic nerve head region of a human subject (left) created by 
summing a 3D data cube in depth (6.0 x 6.0 x 2.0 mm; 200 x 200 x 1024 pixels). A single cross-section through the 
optic nerve, at the level of the red line in the SD-OCT fundus image (right).  
1.2 GLAUCOMA IMAGING WITH OPTICAL COHERENCE TOMOGRAPHY 
 
Primary open angle glaucoma is the second leading cause of blindness in the United States, 
affecting approximately 2% of adults over the age of 40.37, 38 The gradual loss of retinal ganglion 
cell bodies and their axons results in a characteristic thinning of the retinal nerve fiber layer 
(RNFL) seen in glaucoma. However, at least 25-35% of retinal ganglion cells must be lost before 
changes in visual function can be detected using the most sensitive automated visual field testing 
methods.39-41  
OCT has grown to be a clinical standard of care for the assessment of ocular structure 
since becoming commercially available more than a decade and a half ago. Conventionally, the 
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most common scan patterns in glaucoma imaging were a 3.4 mm scan around the optic nerve 
head (ONH), and six equally spaced radial scans through the macula (6 mm) and optic nerve (4 
mm). Retinal nerve fiber layer (RNFL) thickness is obtained via automated RNFL segmentation 
in the circumpapillary scan protocol, while macular thickness (internal limiting membrane, ILM, 
to the photoreceptor inner segment-outer segment junction (IS-OS)) is automatically segmented 
in the macular scan pattern. The optic nerve scan is used to obtain cup area, disc area, cup 
diameter, disc diameter and rim area. Parameters obtained using ONH and RNFL scanning 
protocols have been shown to be different in healthy and glaucomatous eyes,12, 13, 15-17, 42, 43 and 
have good glaucoma discriminating ability.44 In addition, RNFL measurements obtained using 
information from a 3D volume of data have a higher reproducibility as compared to the 
conventional 3.4 mm scan protocol.11 
 Different approaches have been introduced for quantifying 3D RNFL measurements. We 
developed a method for analyzing the measurements in terms of a thickness profile as distance 
from the ONH increased.45 In healthy human eyes, the slope of RNFL thickness increased near 
the margin of the ONH, peaked, and then decreased with increasing distance from the ONH 
center in all but the nasal quadrant, which linearly decreased starting from the disc margin. 
Another approach (Ishikawa H, et al. IOVS 2009;50:ARVO E-Abstract 3328) exploits 3D 
macular data, which have been summarized using segmentation of the inner retinal complex 
(IRC: retinal ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL)). 
This approach reduces IRC data to superpixels (4x4 adjacent sampling points) and compares 
these superpixels to a normative thickness superpixel dataset.  By condensing measurements into 
superpixels, it is less likely that small imaging artifacts or algorithm failure will have an effect. 
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 Despite these novel approaches to analyzing 3D datasets, one critical piece is still 
missing: segmentation of every retinal layer. While it is possible to reliably segment – and 
therefore quantify – strongly reflecting layers such as the RNFL, highly transparent layers are 
nearly impossible to automatically segment. For example, the GCL is nearly impossible to 
reliably quantify using OCT technology in its current state. A method for selectively enhancing 
the contrast from this layer could permit objective quantification of the GCL. If detectable 
glaucomatous changes in the GCL precede changes that can be seen in the RNFL, it may be 
possible to identify the disease in the presence of a contrast agent and start treatment earlier in 
order to preserve vision. In addition, detecting changes in the GCL in a single patient over time 
may enhance longitudinal follow-up. 
1.3 NANOPARTICLES 
In 1959, Richard Phillips Feynman, a physicist at Caltech, gave a lecture at a meeting of the 
American Physical Society entitled, “There’s Plenty of Room at the Bottom.” Feynman 
speculated on the theoretical miniaturization of materials including the advent of a “mechanical 
surgeon” designed to target troubled areas in the body.46  At the time, the term “nanotechnology” 
did not exist, and was not coined until 1974 by Norio Taniguchi. In 1986, K. Eric Drexler 
published the book, Engines of Creation in which he forecasted that nanotechnology would 
revolutionize medicine.  
Since the publication of Engines of Creation, there have been considerable breakthroughs 
in nanomedicine, including the development of biodegradable polymeric nanoparticles for 
targeted drug delivery,47 nanoparticle contrast agents for MRI,48 optical nanosensors,49 
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photothermal destruction of cells50 and more. The American Society for Testing and Materials 
(ASTM) International now officially defines a nanoparticle as, “a sub-classification of ultrafine 
particle with lengths in two or three dimensions greater than 1 nm and smaller than about 100 
nm”.51  
Health-related publications using nanoparticles have grown substantially since early 
papers in 1978 (Figure 4). Given their increased popularity, and potential to aid in in-vivo 
diagnostics and drug delivery, there has been a parallel growth in concern over their effects on 
the human body.52 
 
Figure 4. Number of PubMed publications using nanoparticles from 1978 (first publication) through 2009 
(PubMed search: (nanoparticles) AND "Year"[Publication Date] : "Year"[Publication Date]).  
 Gold nanoparticles may offer a biocompatibility advantage over carbon and iron oxide 
nanoparticles used in medical imaging as contrast agents. Gold salts have been used to treat 
rheumatoid arthritis,53, 54 but the exact mechanism by which they suppress inflammation is 
unclear.55 The literature on the utility and biocompatibility of gold nanoparticles is limited, 
however, as is the scope of their use as medical imaging contrast agents. 
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Nanoparticles in the form of colloidal solid gold spheres, nanorods (GNRs), nanoshells 
and nanocages have been fabricated to induce light scattering and absorbing changes at NIR 
wavelengths.21, 56-61 One of the most suitable biological applications for GNRs is optical imaging 
in the NIR spectral region as a result of their aspect ratio. Both GNRs and gold nanoshells have 
been used by researchers to alter scattering in OCT images.50, 58, 59, 61-65 
1.4 GOLD NANORODS AS OPTICAL IMAGING CONTRAST AGENTS 
When an electromagnetic field is incident upon gold nanoparticles, mobile electrons (plasma) on 
the metal surface collectively oscillate in a phenomenon known as surface plasmon resonance 
(SPR; Figure 5). Particles have a specific resonant frequency that depends on their size and 
shape.66  
 
Figure 5. Demonstration of surface plasmon resonance (SPR). An electromagnetic wave interacts with 
spherical particles and resonance occurs along one axis; when the same wave interacts with nanorod, resonance 
occurs along the long and short dimensions and causes SPR along the length and width of the particle.  
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Spherical (colloidal) gold nanoparticles resonate in one direction because of their 
symmetry, and typically have a resonant wavelength around 520-550 nm (Figure 5, left).66 GNRs 
are defined as solid rod-like particles characterized by their aspect ratio (length divided by 
width). Unlike symmetric gold nanospheres, SPR occurs along the longitudinal and transverse 
dimensions of the rod. When light is incident upon the transverse dimension of the GNRs, the 
result is a resonant wavelength similar to colloidal gold, while the longitudinal dimension results 
in scattering at longer wavelengths (Figure 5, right). Thus, it is possible to tune the resonance 
wavelength of GNRs by changing their dimensions. Longer GNRs exhibit SPR in longer 
wavelengths, and can be tuned to resonate at NIR wavelengths (Figure 6).20, 67 This makes GNRs 
attractive for optical imaging with OCT, where light sources around with a center wavelength of 
850 nm are common. 
 
Figure 6. Theoretical tuning of longitudinal resonance wavelength in GNRs, which is dependent upon 
GNR aspect ratio. Given the same width, longer rods will have a longer resonant wavelength.  
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Investigation into the use of exogenous contrast agents with OCT has been growing in 
recent years. Yang et al used spectral triangulation techniques to map the distribution of 
indocyanine green in the Xenopus laevis using OCT.68 Lee et al used colloidal gold nanoparticle-
coated oil-filled microspheres and OCT to image a mouse liver56 in one of the first studies to 
demonstrate that exogenous OCT contrast agents showed more structural detail as compared to a 
control animal in-vivo.  
Magnetic nanoparticles have been used to enhance contrast in magnetically labeled cells 
in-vitro and in-vivo in Xenopus laevis imaged by OCT in the presence of a magnetic field.69, 70 
While the technique of magnetomotive OCT may be promising, it requires a hardware 
modification of the OCT system to induce magnetic flux. In addition, the potential for thermal 
tissue damage resulting from the oscillation of the magnetic particles in the presence of a 
magnetic field has yet to be determined. 
Several studies have shown the potential for gold nanoparticles to be used as scattering 
contrast agents for detection by OCT.50, 56-59, 61, 63 Gold is potentially a realistic candidate for 
contrast agent material because of its biocompatibility.71 As previously discussed, gold 
nanoparticles also have a strong SPR in the visible and NIR region of the electromagnetic 
spectrum.20, 67 Because they have tunable optical resonances that can be varied over several 
nanometers and OCT imaging takes place at NIR wavelengths, nanoparticles can be designed to 
resonate at or near the center wavelength of an OCT light source.  
Agrawal et al reported successful OCT imaging of gold nanoshells in solution and gold 
nanoshells in a turbid tissue phantom model consisting of polystyrene microspheres in water and 
showed an intensity gain compared to control solution and phantom.59 Different concentrations 
and geometries of the nanoparticles were investigated and resulted in varying intensity changes. 
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Gold nanorods with SPR wavelengths that overlap the OCT source wavelengths were fabricated 
by Troutman et al, who demonstrated an increase in signal of 4.5 dB relative to a polyacrylamide 
tissue phantom using time-domain (conventional) OCT.61  
The ability to functionalize nanoparticles with antibodies that can lead them to molecular 
targets also makes them appealing candidates for optical imaging contrast agents. Such a 
technique has been employed by cancer researchers to target and ablate malignant cells. El-
Sayed et al used colloidal gold nanoparticles conjugated to monoclonal anti-epidermal growth 
factor receptor (anti-EGFR) antibodies and incubated these functionalized particles with a 
nonmalignant epithelial cell line and malignant cell lines.22 The anti-EGFR antibody conjugated 
nanoparticles were bound to the surface of the malignant cells with 600% greater affinity as 
compared to nonmalignant cells as determined by microabsorption spectra and light scattering 
images. Similarly, Sokolov et al describe enhanced scattering from gold colloid nanoparticles 
conjugated to anti-EGFR for targeted optical imaging of cervical cancer cells.23  
To our knowledge, there have not been any studies using antibody-coated nanoparticles 
as contrast agents for ocular OCT imaging. Because the use of OCT in ophthalmology is 
widespread and rapidly growing, the field could benefit tremendously from the development of a 
contrast agent that can target specific ocular components.  
1.5 PROJECT OBJECTIVES 
Our goal is to alter local optical scattering properties of tissue so they can be detected by OCT. It 
is imperative to first determine how these particles interact with ocular tissue and whether they 
will specifically bind to structures of interest. The distribution and behavior of gold nanoparticles 
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after introduction into the eye is not documented. The organizing hypotheses of this dissertation 
were that nanoparticles could improve contrast by modulating the intensity of backscattered light 
detected by OCT and that they could be directed to ocular structures of interest using antibodies 
specific to cellular markers. To examine these hypotheses, the following objectives were 
realized:  
1.5.1 Objective 1 
To establish a reliable method for OCT imaging of the healthy and diseased mouse eye in order 
to provide a platform for testing the utility of OCT contrast agents for ocular imaging.  
1.5.2 Objective 2  
To develop antibody-conjugated gold nanoparticles suitable for targeting specific structures and 
enhancing OCT image contrast in the mouse eye.  
1.5.3 Objective 3 
To examine the localized contrast-enhancing ability and biocompatibility of gold nanoparticle 
contrast agents in-vivo. 
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2.0  MOUSE IMAGING WITH OPTICAL COHERENCE TOMOGRAPHY 
Murine imaging with OCT is becoming increasingly popular given their relatively low cost and 
short lifespan – and therefore shorter time for disease progression. In addition, many transgenic 
models are easy for researchers to access. OCT has been used to study ocular dimensions72 and 
characterize normal eye growth73 as well as growth of eyes in mouse models of myopia.74 Mouse 
models of retinal degeneration have been imaged using time-domain OCT,75, 76 and healthy and 
degenerative mice with SD-OCT.77-84 While these studies provided qualitative structural 
evidence of change associated with retinal degeneration, automated measurements were not 
available. The ability to automatically obtain measurements from 3D scans of the mouse retina 
may provide the objective, quantitative analysis necessary for disease monitoring. 
2.1 REPRODUCIBILITY OF MEASUREMENTS IN HEALTHY MICE 
In human eyes, retinal thickness and retinal nerve fiber layer thickness measurements obtained 
with OCT have been shown to be reproducible,5, 7, 8, 11, 85-90 and this has made OCT valuable for 
cross-sectional and longitudinal studies.91-93 
In mice, time-domain OCT has been used to obtain cross-sectional images of the retina 
in-vivo.75, 76, 78 SD-OCT, which has faster scanning rates and higher axial resolution, allows the 
acquisition of 3D volumetric scans in mice.77, 79-82, 84, 94-96 Despite acquiring volumetric 
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information in mice, thickness measurements obtained post-hoc were often based on single 
cross-sections.79, 81 
In considering the use of SD-OCT for the longitudinal follow-up of mouse models of 
retinal diseases, however, a method for consistently acquiring 3D data must be developed. The 
goal of this study was to evaluate the reproducibility of a method for measuring total retinal 
thickness (TRT) in mice using SD-OCT. 
2.1.1 Methodology: Animals, Imaging, Alignment Considerations and Image Registration 
This experiment was approved by the University of Pittsburgh’s Institutional Animal Care and 
Use Committee and adhered to the Association for Vision Research in Ophthalmology (ARVO) 
Statement for the Use of Animals in Ophthalmic and Vision Research. 
Healthy adult male C57Bl/6 mice (Jackson Laboratory, Bar Harbor, ME) were used in 
this study. Mice were maintained in the University of Pittsburgh Animal Facility with a 12-hour 
light/dark cycle and free access to water and standard laboratory feed.  
Mice were anesthetized with an intraperitoneal injection of ketamine (Ketaject, Phoenix 
Pharmaceuticals, St. Joseph, MI; 80 mg/kg) and xylazine (Xyla-ject, Phoenix Pharmaceuticals, 
St. Joseph, MI; 5 mg/kg) in order to prevent large movements during SD-OCT image 
acquisition. Both pupils were dilated using a topically applied drop of Tropicamide (1%; Falcon 
Pharmaceuticals, Fort Worth, TX). In order to neutralize corneal optical power and focus the SD-
OCT beam onto the retina, a thin glass cover slip was applied to the cornea and 
hydroxymethylcellulose ophthalmic demulcent solution (Goniosol 2.5%; Akon, Buffalo Grove, 
IL) was used to preserve corneal hydration and couple the cover slip to the cornea. Mice were 
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secured on a custom stage (Figure 7), which allowed for free rotation in order to align the eye for 
imaging of the optic nerve head (ONH). 
 
Figure 7. Side (left) and top (right) views of custom stage used for alignment of the mouse for SD-OCT 
imaging of the optic nerve head. A cover slip was used to neutralize the power of the mouse cornea (green arrow). 
Gabriele ML et al. Reproducibility of SD-OCT TRT Thickness Measurements in Mice. Invest Ophthalmol Vis Sci 
2010 Jun 23 [Epub ahead of print].Copyright held by the Association for Vision in Research and Ophthalmology. 
 
Three repeated volumetric images, centered on the ONH, were acquired in both eyes 
(Bioptigen, Inc, Research Triangle Park, NC). All SD-OCT images consisted of 250 averaged A-
scans (each A-scan was an average of 4 consecutive repeated A-scans), 250 frames, and 1024 
samplings in depth. This corresponds to a volume of approximately 1.5 x 1.5 x 2.0 mm at the 
surface of the cover slip. Mice were repositioned in between each scan by rotating the stage 
(when switching between left and right eyes), or removing the mouse from the stage and 
completely repositioning (when returning to the same eye). Care was taken to ensure all three 
scans were acquired before mice developed reversible cataract;97 all images were acquired within 
20 minutes after receiving anesthesia. 
  18 
Since repositioning the mouse between scans resulted in variability in the location and 
orientation of the ONH, we manually aligned the SD-OCT enface images after acquisition 
(Figure 8) to compensate for orientation variability. The first SD-OCT enface image acquired in 
a given eye was used as an alignment reference for subsequent images, and the coordinates of 
rotation and translation for each scan relative to reference were used to align thickness 
measurements as described below. We did not correct for magnification. 
 
Figure 8. Manual alignment of two SD-OCT enface images. (A) Reference SD-OCT enface image and (B) 
subsequent SD-OCT enface image. (C) Subsequent scan registered to reference. Gabriele ML et al. Reproducibility 
of SD-OCT TRT Thickness Measurements in Mice. Invest Ophthalmol Vis Sci 2010 Jun 23 [Epub ahead of print]. 
Copyright held by the Association for Vision in Research and Ophthalmology. 
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 The ONH margin for each eye was manually located by one experienced operator (MG) 
on each OCT enface image. The geometric center of the ONH margin was then used as a center 
point for subsequent analysis. TRT was automatically measured within a sampling band of 
retinal thickness with an inner radius of 55 pixels and an outer radius of 70 pixels (330-420 µm 
at the surface of the coverslip), centered on the ONH, using custom segmentation software to 
detect the internal limiting membrane (ILM) and retinal pigment epithelium (RPE; Figure 9). 
This sampling band was chosen to avoid regions within the optic nerve and areas of vignetting, 
as automated segmentation is not possible in those regions. After sampling band thickness 
information was obtained, scans were rotated and translated based on the coordinates obtained 
from manual image alignment. These aligned thickness measurements were used to assess 
reproducibility. It should be noted that alignment was completely independent of thickness 
measurements. In addition, there was often a motion artifact that occurred during acquisition as 
the result of respiration, as evident by the high frequency motion artifact seen in Figure 9. This 
was not corrected for when aligning fundus images. 
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Figure 9. SD-OCT enface image (left) with the red line indicating the location of the OCT B-scan (right). 
The B-scan demonstrates automated segmentation of the internal limiting membrane (ILM, white line) and retinal 
pigment epithelium (RPE, blue line) to obtain total retinal thickness measurements. The vertical gray lines represent 
the disc margin.  
 
 SD-OCT enface images were checked to ensure that there was consistent image quality 
across the scan and that there were no areas of shadowing from media opacities within the TRT 
sampling band, as this could affect thickness measurements. Eyes were excluded if the TRT 
segmentation algorithm failed at any location inside the sampling band. 
 Algorithm failure was defined as a clear disruption of the border, either ILM or RPE, for 
greater than 5 consecutive A-scans within the sampling band. If any one of the three scans per 
eye had to be excluded, the mouse (both eyes) was excluded from the analysis. 
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2.1.2 Statistical Analysis 
Linear mixed effects models were fitted to global and quadrant TRTs, taking into account the 
clustering between eyes, in order to assess measurement reproducibility. Imprecision (as 
measured by the residual standard deviation (SD)) and corresponding 95% confidence intervals 
were computed. All analysis was conducted using R Language and Environment for Statistical 
Computing program (http://www.R-project.org; date accessed: February 1, 2010). An α level of 
0.05 was used as a cutoff for statistical significance. 
The mixed effects model for TRT (yijk) for mouse i, eye k nested within mouse i, and 
replicate k is: 
yijk = α + ai + bij + εijk, 
 
where α represents the cohort mean TRT, ai is the random intercept for mouse i (assumed to be 
Normally distributed with mean 0 and standard deviation σm (ai ~ N(0,σm2)), bij is a random 
intercept for eye j nested within mouse i (bij ~ N(0,σe2)), and εijk is a Normally distributed 
random error (εijk~ N(0,σ2)) . The standard deviations σm and σe represent the variability of the 
thickness measurements coming from the cohort of mice (heterogeneity across mice and eyes, 
respectively), while the error standard deviation represents the imprecision coming from the 
device. This device-related imprecision includes error coming from segmentation algorithm 
performance as well as the manual alignment of SD-OCT enface images. 
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2.1.3 Results 
Thirty eyes from 15 healthy adult male mice, age 13 weeks, were imaged in this study. Two eyes 
were excluded due to segmentation algorithm failure, one at the level of the RPE and one at the 
ILM. The contralateral eyes from those two mice were also excluded. In total, 26 eyes from 13 
healthy adult male mice were included in this study. Figure 10 shows one example of alignment 
of TRT maps relative to reference. 
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Figure 10. Total retinal thickness maps aligned to a single reference scan. (A, C, F): SD-OCT enface 
images; (B, D, G): Total retinal (TR) thickness map with sampling region indicated as the region between red 
concentric circles (E, H): Total retinal thickness maps, registered to reference. Gabriele ML et al. Reproducibility of 
SD-OCT TRT Thickness Measurements in Mice. Invest Ophthalmol Vis Sci 2010 Jun 23 [Epub ahead of 
print].Copyright held by the Association for Vision in Research and Ophthalmology. 
 
Mean global TRT across all eyes was 298.21 μm (Table 1), with a mouse heterogeneity 
SD of 4.88 μm (coefficient of variation (CV) = 0.016) and an eye SD of 3.32 μm (CV= 0.011). 
The device-related global imprecision SD was 2.33 μm (CV = 0.008). The superior quadrant 
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showed the thickest TRT measurements (310.38 μm, mouse heterogeneity SD 6.09 μm (CV = 
0.020), eye SD 6.98 μm (CV = 0.022)) while the inferior quadrant was the thinnest (291.55 μm, 
mouse heterogeneity SD 6.02 μm (CV = 0.021), eye heterogeneity SD 8.13 μm (CV = 0.028)). 
The highest (worst) quadrant imprecision SD was in the superior quadrant (3.13 μm; CV = 
0.010) and lowest (best) in nasal quadrant (2.06 μm; CV = 0.007). 
 
Table 1. Estimates of mixed effect model parameters and coefficient of variation (CV) for global and sectoral total 
retinal thickness. All estimates are in microns (µm) except for CV, which is unitless. 
Sector Estimated Mean (α) 
Estimated SD Imprecision SD 
Mouse Eye SD* (σ) CV 
σm CV σe CV 
Global 298.21 4.88 0.016 3.32 0.011 2.33 0.008 
Temporal 294.37 6.17 0.021 4.80 0.016 3.05 0.010 
Superior 310.38 6.09 0.020 6.98 0.022 3.13 0.010 
Nasal 296.52 4.61 0.016 6.08 0.021 2.06 0.007 
Inferior 291.55 6.02 0.021 8.13 0.028 3.09 0.011 
* Device reproducibility measurement 
 
2.1.4 Summary and Discussion 
In this study, we were able to demonstrate good intravisit reproducibility of SD-OCT TRT 
measurements in mice that were obtained using automated retinal segmentation software. This 
lays the foundation for future studies monitoring retinal changes in mice over time. We showed 
global imprecision estimates were 2.33μm. Hence, a TRT difference between two observations 
from the same eye of the same mouse of at least 6.46μm  (2.33μm * 1.96 * √2; 2.17% of the 
mean TRT; 3.31 pixels) would be necessary to conclude, with 95% confidence, that the 
difference was due to an actual structural change as opposed to variability inherent to the device. 
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While the superior quadrant showed the worst quadrant imprecision SD (3.13 μm), the 
superior CV (0.010) was actually slightly better than that of the inferior quadrant (CV = 0.011). 
This discrepancy is attributed to the differences in thickness within those quadrants: the superior 
quadrant had the thickest measurements, while the inferior quadrant measurements were thinnest 
(310.38 μm versus 291.55 μm, respectively). Overall, the CV was similar for the superior, 
inferior and temporal quadrants, but was lower in the nasal quadrant (CV = 0.007). Our study 
was designed to evaluate intravisit reproducibility, as mice were only anesthetized once and 
repeatedly scanned in one session. This was observed in multiple studies to be the main source of 
variability with OCT imaging.98, 99 Intervisit variability has been shown to add minimal 
variability and was therefore not the focus of this study.99 
While our TRT measurements are thicker than those reported by Horio et al,75 they only 
reported temporal retinal thickness from a single A-scan at a distance of 1-2 disc diameters from 
the temporal margin of the optic disc. This was further from the disc center than we measured 
and can therefore be expected to show a lower retinal thickness.45 In addition, since their 
measurement was based on a single A-scan, there may have been large variability in their 
measurements. They also used a lower resolution OCT system as well as a different strain of 
mice (Balb/c), which was older (16 weeks), all of which may explain the observed differences. 
Li et al76 showed retinal thickness measurements of approximately 200-250 µm in C57Bl/6 mice. 
Their measurements were based on single cross-sections and used a lower resolution OCT 
system. Ruggeri et al94 measured retinal thickness using SD-OCT and reported an average retinal 
thickness of 202 µm. This average was based on all points outside of a 0.5 mm-diameter region 
covering the ONH, while our sampling location was within a band with a diameter of 55-70 
pixels. We chose this sampling region to ensure that we were sampling outside the ONH region 
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and not extending into a region where there could be vignetting of the image from the pupil. 
Compared to our sampling region, their average included thinner regions of the retina, which 
may explain the difference in global measurements. In addition, differences in measurements due 
to different devices with different segmentation algorithms may partially explain this 
discrepancy. This may also explain the slight differences in our measurements as compared to 
those reported by Kim et al,79 Huber et al,81 Fischer et al,84 and Cebulla et al.96 
We observed slightly thinner TRT measurements inferiorly, which was unexpected. One 
reason for this finding may be that the orientation of the eye during scanning is not the true 
orientation of the mouse, since mice were rotated on a stage during acquisition to allow for 
focusing on the optic nerve head. This might have lead to variability of the exact quadrant 
boundary locations across eyes. This is a limitation inherent to our method for obtaining images 
centered on the ONH by rotating the mouse on a stage.  
Another limitation of this study is that it requires manual labeling of the optic disc margin 
to obtain the geometric center of the disc. It is possible, however, that automated detection of the 
ONH (and ONH center) may be available in the future, similar to how it is currently detected in 
human eyes.100 In addition, we used manual registration of enface images to account for 
rotational and translational eye position differences from scan to scan. This was necessary to 
account for shifts that occurred between scans because our stage allowed for rotation and 
translation of the eye in order to center the image on the ONH and account for x- and y- scan 
location differences. A stage that allows for more consistent alignment of mice between scans 
may alleviate this. It may also be possible to use automated registration based on blood vessel 
segmentation in enface images to eliminate the manual component of the analysis. Future studies 
investigating this are necessary.  
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We have shown that SD-OCT allows reproducible minimally-invasive 3D scanning of 
tissue structure in-vivo. Because of this, SD-OCT has the potential to reduce the number of mice 
needed in studies of diseases that affect retinal structure by allowing the same mice to be 
consistently followed from visit to visit. This means that longitudinal studies monitoring one 
population of mice are possible, as opposed to the current approach of cross-sectional analysis 
with a subset of mice at multiple time points. This will allow researchers to better observe the 
structural manifestations of disease over time, as demonstrated in the next section. 
2.2 QUANTIFYING RETINAL THICKNESS CHANGES IN RESPONSE TO INJURY 
Retinal ganglion cell (RGC) death induced by optic nerve crush injury has been used as a model 
to investigate axonal degeneration of the central nervous system in mice.101-104 In adult mice, 
approximately 60% of RGCs are lost within three weeks after optic nerve crush injury, as 
determined by histology.101, 104 
Ophthalmic imaging techniques such as confocal scanning laser ophthalmoscopy (CSLO) 
and OCT can provide quantitative and detailed structural information from the retina and optic 
nerve head (ONH) region. In-vivo images of RGCs in mice and rats after optic nerve crush have 
been acquired using retrograde labeling and CSLO.105-107 Recently, Leung et al demonstrated the 
use of CSLO with Thy-1 cyan fluorescent protein expressing transgenic mice, to monitor RGCs 
in-vivo after nerve crush.108 The authors in these studies were able to observe the loss of RGCs in 
the same eyes over time, contrary to previous experiments using histology that required several 
different animals at each time point. 
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OCT allows for non-invasive, in-vivo imaging of ocular structures, and has been used to 
obtain optical cross-sections of the mouse retina.75-78 Time-domain OCT75, 76 and spectral-
domain (SD)-OCT79, 81, 83, 94, 109 imaging have been used to observe retinal thinning in mouse 
models of retinal degeneration. One study used SD-OCT to image axotomized rats, and manually 
obtained measurements of retinal layers in six cross-sectional images.110 This approach, 
however, is prone to subjective bias both in the selection of individual cross-sections and the 
manual segmentation of retinal layers. In order to fully benefit from the high resolution and rapid 
scanning provided by SD-OCT imaging, it would be desirable to obtain automated 
measurements from the area of interest. The goal of this study, therefore, was to investigate the 
longitudinal effect of optic nerve crush injury on total retinal thickness (TRT) in adult mice using 
automated segmentation analysis of SD-OCT images.  
2.2.1 Methodology 
This experiment was approved by the University of Pittsburgh’s Institutional Animal Care and 
Use Committee and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. 
Healthy adult male C57Bl/6 mice (Jackson Laboratory, Bar Harbor, ME) were used in 
this study. Mice were maintained in the University of Pittsburgh Animal Facility with a 12-hour 
light/dark cycle and had free access to water and standard laboratory feed. Control animals were 
not exposed to any surgical procedure, while nerve crush animals had one optic nerve that was 
crushed. 
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Nerve Crush Procedure 
Animals were anesthetized with an intraperitoneal injection of ketamine (Ketaject, 
Phoenix Pharmaceuticals, St. Joseph, MI; 80 mg/kg) and xylazine (Xyla-ject, Phoenix 
Pharmaceuticals, St. Joseph, MI; 5 mg/kg). An incision was made in the conjunctiva at the 
limbus and then the sub-Tenon’s space was bluntly dissected posteriorly.  The muscle cone was 
entered and the optic nerve exposed. The optic nerve was crushed with fine forceps for 3 
seconds, approximately 1 mm posterior to the globe, under direct visualization (Figure 11). Care 
was taken not to damage surrounding blood vessels.  
 
Figure 11. Optic nerve exposed for nerve crush surgery. Photo courtesy of C. Leung. 
 
SD-OCT Imaging 
Prior to each session, mice were anesthetized with an intraperitoneal injection of 
ketamine and xylazine in order to prevent large movements during SD-OCT image acquisition. 
Pupils were dilated using a topically applied drop of Tropicamide (1%; Falcon Pharmaceuticals, 
Fort Worth, TX). To neutralize corneal optical power and focus the SD-OCT beam onto the 
retina, a thin glass cover slip was applied to the cornea. Hydroxymethylcellulose ophthalmic 
demulcent solution (Goniosol 2.5%; Akon, Buffalo Grove, IL) was used to preserve corneal 
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hydration and couple the cover slip to the cornea. Mice were secured on a custom stage that 
allowed for free rotation in order to acquire images centered on the ONH.111 All images were 
acquired within 20 minutes of the onset of anesthesia to avoid a reduction in signal intensity that 
can be caused by the occurrence of reversible cataract.97 
Volumetric images centered on the ONH (250 x 250 A-scans, 1024 samplings in depth 
per A-scan; 1.5 x 1.5 x 2.0 mm at the surface of the cover slip) were acquired using SD-OCT. 
Four consecutively repeated A-scans were collected and averaged at each location to improve 
signal-to-noise ratio.  A SD-OCT scan obtained in each eye prior to nerve crush served as 
baseline in each nerve-crushed eye while the first imaging session was used as baseline in the 
control eyes. Follow-up scans were obtained at multiple days, up to 32 days post nerve-crush in 
both groups. 
SD-OCT Image Analysis and Automated Segmentation 
 Since mice were rotated freely on our stage, and eyes could be oriented differently from 
scan to scan, we manually aligned SD-OCT enface images and performed automated 
segmentation from the ILM to the RPE as described in Section 2.1.1 and shown in Figures 8-
10.111 As in Section 2.1.1, TRT measurements within a sampling band with radii of 55-70 pixels 
(330-420 µm at the surface of the coverslip), centered on the ONH, were used. Scan were 
subsequently rotated and translated based on the coordinates obtained from manual image 
alignment, and global and sectoral average TRTs were computed. These aligned TRT 
measurements were used to assess retinal thickness changes over time. 
SD-OCT Image Quality Analysis 
 SD-OCT enface images were subjectively checked to ensure that there was consistent 
image quality across the scan, and that there were no areas of shadowing from media opacities 
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within the TRT sampling band. In addition, we measured the quality index, as previously 
described,112 along every A-scan in the data volume. 
2.2.2 Statistical Analysis 
Linear mixed effects models with polynomial (quadratic) terms were fitted to describe global and 
sectoral (temporal, superior, nasal, inferior quadrants) TRT of nerve crush and control eyes over 
time, with scan quality index included as a covariate in the analysis. This mixed effects analysis 
accounted for the repeated measurements over time and the use of both eyes from some animals. 
All analysis was conducted using R Language and Environment for Statistical Computing 
program (http://www.R-project.org; date accessed: March 22, 2010). An alpha level of 0.05 was 
used as a cutoff for statistical significance. 
2.2.3 Results 
Eight eyes from four healthy control mice  (baseline age 64 ± 0 days) and eleven eyes from 
eleven nerve crush mice (baseline age 76 ± 11.8 days) were included in this study. All control 
eyes were scanned at baseline and eight consecutive sessions over the course of 31 days, while 
nerve-crushed eyes were followed for up to 32 days (average time of follow-up: 29.2 ± 4.0 days, 
average number of sessions 9.9 ± 0.7). In the control eyes, 4% (3/72) of global and 2% (7/288) of 
quadrant TRT measurements were excluded based on our quality criteria. These segments were 
excluded due to algorithm failure caused by low signal. In the nerve-crushed eyes, a total of 39% 
(43/109) of global and 29% (126/436) of quadrant TRT measurements were excluded. There was 
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a higher incidence of poor signal quality caused by shadowing from media opacities in nerve-
crushed eyes, which caused algorithm failure. 
Mean TRT across all eyes at baseline was 299.7 ± 8.3 μm. TRT showed an initial period 
of thickening, followed by a steep decrease and slight increase after day 21 in the nerve-crushed 
eyes (Figure 12). There was a statistically significant positive quadratic term in nerve-crushed 
eyes (p < 0.05 for global and sectoral measurements), but not in control eyes, which can be 
attributed to the initial phase of thickening. Control eyes showed a slight but statistically 
significant increase in slope over time (p < 0.05 for global and sectoral measurements). The 
fitted models for the nerve crush group showed a statistically significantly difference from 
control for both linear and quadratic components (p < 0.05) for global and sectoral 
measurements. Image quality did not significantly affect TRT measurements for control or 
nerve-crushed eyes, except for the superior quadrant in nerve-crushed eyes (p < 0.05). 
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Figure 12. (Top) Individual total retinal thickness (TRT) measurements, each eye represented by a 
different color and (Bottom) mean global TRT over time for control and nerve-crushed eyes; the solid line 
represents mean thickness and dashed lines represent the standard deviation.  
 
In order to eliminate the potential confounding effect of the initial TRT increase on the 
analysis, we performed a post hoc analysis using mixed effects modeling with TRT 
measurements acquired on or after day six, once the transient thickness increase resolved. Global 
and all sectoral measurements from nerve-crushed eyes had a statistically significant negative 
slope (p < 0.05). There was a statistically significant positive quadratic term for global 
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measurements as well as temporal, nasal and inferior quadrants (p < 0.05), and quality index was 
not a statistically significant covariate in any sector. There was no statistically significant 
quadratic term in the control eyes, but there was a statistically significant slight linear increase in 
thickness over time in global measurements as well as superior and inferior quadrants (p < 0.05). 
2.2.4 Summary and Discussion 
In this study, we demonstrated that quantification of longitudinal TRT changes is possible in 
untreated mice and following optic nerve crush using OCT with automated segmentation. We 
were able to follow a cohort of mice over time and therefore did not have to sacrifice mice at 
each time point to obtain structural information. This enables a true longitudinal assessment as 
opposed to attempting to extract a longitudinal effect from multiple cross-sectional data as in the 
case of histological sectioning. In addition, this can substantially reduce the number of animals to 
be used in such experiments. 
The initial phase of retinal thickening that was seen in the nerve-crushed mice may be 
due to an inflammatory reaction causing transient edema. It is possible that this finding has not 
been reported previously because the increase of ~25μm in TRT is difficult to detect clinically. 
Histological studies investigating retinal response to nerve crush observed mice at later time 
points and therefore missed early inflammation. In addition, dehydration and tissue shrinkage 
that occurs while processing tissue for histology may prevent edematous changes from being 
readily apparent. This highlights the advantages of non-invasive cross-sectional in-vivo tissue 
assessment. 
While our crush procedure consisted of a single 3-second crush, the duration of the crush 
may affect the severity of damage and the persistence of early retinal thickening. It is possible 
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that exposure to a longer crush may induce a larger response, but we chose to limit the length of 
the crush in order to assess the utility of this imaging approach and to avoid complete axotomy 
or blood vessel damage. 
Previous reports have shown a decrease in retinal ganglion cell count of ~60% by three 
weeks post-lesion.101, 104 While our results showed a decrease in thickness over time, our method 
is currently limited to measurements of the entire thickness of the retina. Hence, the exact axial 
location of changes within the retina is not known. It is possible that segmenting the RGC or 
retinal nerve fiber layer may show an even more noticeable decrease in thickness. However, at 
this stage, automated retinal nerve fiber layer thickness measurements are unreliable in mice 
because the retinal nerve fiber layer is especially thin. 
Another limitation of this study is that it is possible that exact sectoral boundary locations 
could vary from mouse to mouse due to the rotation of mice on the stage. We could correct for 
rotation in follow-up images for a given mouse using the method described above, but this 
adjustment is less reliable across mice. For this reason, we chose not to assess clock hour 
measurements and to include only global and quadrant thicknesses in the analysis. Global 
measurements would not be affected by this limitation since all measurements within the band 
are compared. 
We observed that more sectors from nerve-crushed eyes had to be excluded due to poor 
image quality than from control eyes. The media opacities leading to poor image quality were 
often due to corneal opacities, suggesting that eyes that received the nerve crush injury were 
more sensitive to damage from the cover slip used to focus on the retina. This may be due to 
corneal dehydration caused by the extended time of recovery from anesthesia after surgery, or 
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because the optic nerve crush surgery affects the conjunctiva, inhibiting proper hydration and 
tear film coverage. 
We observed a slight linear increase in retinal thickness in control eyes over the course of 
this experiment. The significant positive quadratic term in the nerve crush eyes indicates that 
there was a rebound in thickness in those eyes as well. Previous studies have shown that the 
mouse eye113, 114 and retina115 are still growing through at least 15 weeks after birth. The follow-
up period in our study lasted to an age of 15 weeks, which may explain the increase in retinal 
thickness in control eyes and the rebound in thickness in nerve-crushed eyes. The rebound in 
TRT in nerve-crushed eyes may also be due to retinal response to inflammation, such as gliosis. 
Another potential explanation for the gradual thickening might be related to scan quality. OCT 
studies in humans demonstrated that an increase in signal quality leads to an increase in 
thickness measurements.116-118 However, image quality was included as a covariate in our mixed 
effects model and did not have a statistically significant effect. Nevertheless, it should be noted 
that our quality criteria excluded images that were of poor quality, which might explain the 
discrepancy between our findings and those reported previously. 
We did not include the contralateral eyes of the nerve-crushed mice as a control in this 
experiment, as there is evidence that there may be change occurring in those eyes.119-121 Future 
studies measuring retinal thickness in the contralateral eyes are required in order to determine 
whether they undergo structural changes that are detectable with OCT.  
In summary, we demonstrated the ability of OCT to detect retinal thinning in-vivo 
following nerve crush. Using OCT to monitor retinal thickness in the mouse optic nerve crush 
model may be valuable for evaluating the pathophysiology of disease as well as testing the 
efficacy of treatment, since the same animals can be followed over time. 
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2.3 SUMMARY AND DISCUSSION: MOUSE IMAGING WITH OCT  
The noninvasive nature of image acquisition together with the commercialization of systems 
optimized for laboratory use has resulted in a recent increase in the number of animal studies 
using OCT. Two- and three-dimensional scanning with OCT is appealing because the same 
animals can be followed over time, in-vivo, making longitudinal studies of ocular structures 
possible without the need to sacrifice animals at various time points and obtain histological 
sections. Not only does this reduce the number of animals required for experiments, but is 
superior to cross-sectional experiments which require different animals for different time points. 
Ultimately, longitudinal OCT animal studies may help evaluate the efficacy of 
pharmacological agents, stem cell therapies, surgical intervention, and retinal prosthetics while 
reducing the required number of animals.  OCT has the potential to provide a better 
understanding of disease development and progression in transgenic and other models of disease, 
which may eventually translate to improved clinical assessment and understanding of disease. 
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3.0  GOLD NANOROD PREPARATION 
There are several published approaches for GNR fabrication, including wet chemical,122 
electrochemical,123 or photochemical124 synthesis. The wet chemical synthesis approach utilizes a 
surfactant as a scaffold for growing rods from spherical colloidal gold seed particles. A colloidal 
gold spherical seed solution is added to a surfactant-based growth solution, and growth of the 
colloidal particles occurs along a single axis, forming the longitudinal dimension of the rod.  
This approach is appealing because it is easy to monitor growth of the particles by observing the 
color and measuring the UV-Vis-NIR spectrum of the growth solution as it reacts with the seed 
solution. 
3.1 PREPARATION OF GOLD NANORODS RESONANT AT ~850 NANOMETERS 
As described in Section 1.4, gold nanoparticles are an appealing candidate for optical 
imaging contrast enhancement not only because gold is mostly an inert immunologic compound, 
but also because gold exhibits the SPR phenomenon, which may boost backscattered signal 
intensity. Since the physical size or aspect ratio can influence the resonant frequency of 
nanoparticles, changing these parameters allows for tuning of the SPR to wavelengths of interest. 
SPR is observed in gold at NIR wavelengths,20, 21, 58, 60, 125, 126 and gold nanoparticles are thus 
potentially applicable to ocular OCT imaging at 840-860 nm. 
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GNRs can be reliably synthesized with dimensions on the order of 20-80 nm, making 
them especially useful for biological applications. The goal of this study was to fabricate 
scattering GNRs that could enhance reflectivity within a spectral-domain ocular OCT system. 
3.1.1 Seed-mediated, Surfactant Directed Synthesis  
Gold nanorods with an aspect ratio of approximately 4 (~40 nm x 10 nm) were prepared using a 
well-established seed-mediated, surfactant directed wet chemical synthesis122 with a slight 
modification to facilitate the growth of longer GNRs that resonate at longer wavelengths (Figure 
13). The modification steps taken to optimize this protocol are described in Appendix A.  
A seed solution of spherical colloidal gold particles was prepared by mixing 
hexadecyltrimethylammoniumbromide (CTAB; 5ml, 0.20M) with HAuCl4 (5ml, 0.00050M), 
followed by the addition of ice-cold NaBH4 (600µl, 0.010M). A separate growth solution was 
prepared by adding AgNO3 (9ml, 0.0040M) to CTAB (150ml, 0.20M), followed by HAuCl4 
(150ml, 0.0010M). At this point, a small amount of HCl (225µl, 12M) was added to lower the 
pH of the growth solution, followed by the addition of ascorbic acid (2.1ml, 0.0788M). After the 
seed and growth solutions were prepared, 360µl of the brown seed solution was added to the 
colorless growth solution. The growth solution was allowed to sit at 25 oC for 45 min, until the 
color of the solution turned purple-red. 
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Figure 13. (a) Seed-mediated, surfactant directed synthesis preparation of gold nanorods (GNR). (b) Top: 
Photograph of GNR solution after concentrating and removing excess CTAB; Bottom: electron micrograph of PAA-
coated GNRs (c) Absorbance spectrum of PAA-coated GNRs, with resonance peaks at λ = 530nm and λ =835nm 
 
After particle centrifugation (4100 RPM) to remove as much positively-charged CTAB 
as possible, a layer of negatively-charged polyacrylic acid (PAA) was adsorbed onto the surface 
of the GNRs according to the protocol described by Kim et al127 to preclude clustering of 
particles in solution and to provide a shield from any CTAB that remained on the surface of the 
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particles after centrifugation, as CTAB is known to be cytotoxic. After the addition of PAA, the 
concentration of gold in the solution was approximately 51mg/ml. A schematic representation of 
the PAA-GNRs can be seen in Figure 14. Figure 15 shows OCT images of GNRs in solution. 
The GNR solution shows an increase in intensity as compared to PBS.  
 
 
Figure 14. GNRs were prepared in a solution with a potentially cytotoxic, positively-charged surfactant 
(CTAB), so a negatively-charged PAA coating is used to neutralize and shield 
 
 
Figure 15. OCT image of phosphate buffered saline (PBS; sham) and gold nanorod (GNR) solution. 
Enhanced scattering can be observed in the GNR solution (250 A-scans; 2.5 mm). 
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3.2 CHARACTERIZATION OF ANTIBODY-CONJUGATED GOLD NANORODS 
Antibody-conjugated gold nanorods (Ab-GNRs) have the potential to be used for specifically 
targeting or treating tissue using optical imaging techniques.22, 66 While methods for conjugation 
have been reported,128 there is a need to characterize the bioconjugation for preclinical studies 
such that an optimal concentration – maximizing the number of particles that bind while 
minimizing the dosage of particles and excess antibody – can be established. 
Typically, researchers have assessed the level of antibody conjugation by measuring 
surface charge (zeta-potential) of a solution of particles.129 However, zeta-potential is based on 
all components of the gold surface, which also consists of positively and negatively charged 
polymers present to stabilize the particles. Moreover, zeta-potential does not indicate whether 
antibody-conjugated nanoparticles are sticking to structures of interest. Other methods, such as 
enzyme-linked immuno sorbant assays (ELISA) have been reported,130 but can only indicate the 
presence or absence of the antibody and provide no information on whether the antibody-
conjugated particles are functional. In addition, ELISA protocols do not indicate whether there 
are excess antibodies in the solution, so there is potential for false-positive results. 
Immunogold staining is a technique developed for transmission electron microscopy 
(TEM) by Faulk and Taylor in 1971.131 In this technique, colloidal gold particles attached to 
secondary antibodies are used to indicate the presence of a primary antibody. Gold has a high 
density of electrons and thus shows up clearly in TEM images, and secondary antibodies are able 
to bind to primary antibodies. TEM has been used to directly visualize that nanoparticles were 
successfully bioconjugated.130, 132 A limitation of this approach, however, is that it only indicates 
whether the nanoparticles are functionalized and not whether they are capable of functionally 
binding. 
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Flow cytometry may offer a solution to this problem. This technique allows for the 
analysis of cell populations with respect to their size and granularity (Figure 16). Individual cells 
pass through a laser beam in a hydrodynamically focused stream of fluid. The amount of light 
that is projected in line with the beam is proportional to the size of the cell, while the light 
scattered perpendicularly to the beam indicates the relative granularity, internal complexity and / 
or roughness of the cell membrane. In addition, cells can be labeled with fluorescent markers (eg, 
antibodies conjugated with fluorescent labels), to identify subpopulations of cells within a 
sample or to look for the presence of specific markers.  
 
Figure 16. Schematic representation of flow cytometer. Incident laser light is scattered upon reaching an 
individual cell; forward and side scattered light is collected via filters and photodetectors. 
 
The goal of this study was to develop a protocol for characterizing the success of antibody 
conjugation to GNRs using flow cytometry. CD90 (Thy1) is a protein expressed on the surface 
of retinal ganglion cells133 and T-cells.134 Anti-CD90.2 antibody-coated GNRs (Ab-GNRs), 
  44 
therefore, may allow for specific targeting of retinal ganglion cells and T-cells. We hypothesized 
that antibody-coated (α-CD90.2) GNRs (primary antibody) would stick to CD90.2+ (Thy 1.2+) 
tumor cells, and that a fluorescently labeled secondary antibody could be used to detect the 
presence of the primary antibody bound to tumor cells using flow cytometry.  
3.2.1 Methods 
Gold Nanorods 
The nanoparticles used in this experiment were obtained from Nanorods, Inc 
(Germantown, MD), and were coated with either α-CD90.2 (Thy1.2) antibodies (Ab-GNR) or 
polystrene sulfate (PSS-GNR). The GNR solutions had an optical density (OD) of ~50. The 
GNRs were grown using a wet chemical, surfactant-directed synthesis similar to what is 
described above in Section 3.1.1. To conjugate the antibodies and form Ab-GNRs, Nanorods, Inc 
followed a protocol described by Huang et al.128 Briefly, excess CTAB was removed from bare 
GNRs by centrifugation. Next, the positively charged GNRs were exposed to negatively charged 
poly(strenesulfonate) (PSS, MW = 18,000, Polysciences, Inc) polyelectrolyte solutions. Excess 
PSS was removed by centrifuging and the GNR pellet was resuspended in N-(2-
hydroxyethyl)piperazine-N’-2-ethanesulfonic acid (HEPES) buffer. PSS-GNRs were then 
incubated for 20 minutes with α-CD90.2 antibodies diluted in HEPES buffer, and centrifuged 
and resuspended in PBS. 
 
Immunogold Transmission Electron Microscopy Assay 
We used TEM to directly visualize Ab-GNRs with a secondary antibody (2o Ab) label 
that was conjugated to 12 nm colloidal gold particles. This was done by incubating 5 µl Ab-GNR 
  45 
(or 5 µl PSS-GNR) in 25 µl bovine serum albumin (BSA) on a mesh formvar-coated copper grid 
for 4 min. Grids were then washed with BSA followed by 40 min incubation with 12 nm 
colloidal gold anti-Rat immunoglobulin 2o Ab (AffiniPure Goat α RatIgG; Jackson Immuno 
Research). Next, a series of washes in BSA and PBS was performed to remove excess 2o Ab, and 
the grid was fixed using 2.5 % glutaraldehdye and rinsed with PBS. After drying, Ab-GNRs and 
PSS-GNRs were examined directly using a JEOL JEM 1210 transmission electron microscope 
(Peabody, MA). 
 
GNR Cell Staining Assay for Flow Cytometry 
Mouse lymphoma cells (EL-4), which express CD90.2 (Thy1.2), were used in this 
experiment, which is summarized in Figure 17. Approximately 2 x 105 tumor cells were placed 
in each of seven wells in a 96 well plate and stained with either 10 µl Ab-GNR solution or 10 µl 
supernatant from the Ab-GNR solution. We assayed the supernatant from the Ab-GNR solution 
to observe whether there were free antibodies present in the Ab-GNR solution, and washed the 
Ab-GNRs twice, assaying both washes and supernatants, to look for a titration effect. The 
supernatant from the Ab-GNR solution and washes were obtained by centrifuging 50 µl Ab-
GNR solution (or washes) for 10-15 min at 10,000 RPM in a microcentrifuge. Washes consisted 
of 1.5 ml PBS (first wash) or 0.5 ml PBS (second wash); a smaller volume was used for the 
second wash to avoid removing too much of the PSS-coating, as this would induce clustering of 
GNRs.  
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Figure 17. Summary of methodology for flow cytometry assay of EL-4 tumor cells (Thy1.2+), using 
antibody-coated (αCD90.2/αThy1.2) GNRs solutions washed up to two times and their corresponding supernatants. 
The secondary antibody (2o) was APC-conjugated.  
 
A fluorescently labeled secondary (2o) antibody (APC conjugated Goat α-Rat; BD 
Pharmingen) was used to indicate the presence of α-CD90.2. Our seven test conditions are 
summarized in Figure 17, upper right. 
Each well was incubated with either Ab-GNR or the supernatant from Ab-GNR solution 
for 20 minutes and then washed twice with FACS buffer. For 2o Ab staining, solutions were 
stained for 15 minutes on ice in the dark and then washed twice with FACS buffer. Samples were 
  47 
run on a FACSAria (BD Biosiences, San Jose, CA) flow cytometer and the percentage of cells 
emitting an APC signal was obtained using FlowJo software (Tree Star, Inc, Ashland, OR). 
3.2.2 Results 
TEM images show co-localization of Ab-GNRs with 2o Ab label that is not present in the 
PSS-GNR solution (Figure 18). Some background 12 nm 2o Ab labels were present, indicating 
there were excess antibodies in the solution that stuck to the TEM grid.  
 
 
Figure 18. TEM showing labeling of Ab-GNRs with 2o Ab-conjugated 12 nm gold colloidal spheres. Most 
Ab-GNRs had a single 2o label, and some free 12 nm colloidal spheres indicate the presence of free antibodies. PSS-
GNRs were not labeled.   
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While the majority of Ab-GNRs had one 2o Ab label per GNR, there were some particles 
that were not labeled, and some had up to three labels (Figure 19). A theoretical schematic 
representation of the gold nanorod, CTAB and PSS coatings, and antibodies is shown in Figure 
19 for reference. 
 
Figure 19. TEM showing a single Ab-GNR labeled with three colloidal gold 2o Ab. Each Ab-GNR is 
coated with PSS to shield from any CTAB layer leftover from production of the particles. 
 
Results from the flow cytometry assay are seen in Figure 20. Ab-GNRs show a strong 
APC signal in the presence of the 2o Ab (92.70% of cells are labeled). However, there are excess 
antibodies in the solution, as indicated by the fluorescence signal in the supernatant (94.28% 
labeled). Washing the particles caused a substantial decrease in the amount of excess antibody in 
the supernatant (0.59%), bringing it back down to the level of the control solution (0.48%). 
However, many of the Ab-GNRs were lost in the process, and only 3.64% of cells were labeled 
after one wash. Washing a second time further reduced the fluorescence signal coming from the 
supernatant (0.22%) and caused even greater loss of Ab-GNRs (1.30%).   
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Figure 20. Results of flow cytometry assay. Top panel: stock Ab-GNRs and supernatant; Middle panel: 
Ab-GNR solution and supernatant after a single wash; Bottom panel: Ab-GNR solution and supernatant after two 
washes. The subset gate indicates the percentage APC-positive cells; more densely-packed cell populations are 
indicated by hotter colors.  
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3.2.3 Discussion 
We developed a flow cyometry assay to determine whether Ab-GNRs are binding to cells of 
interest. This approach offers a novel way to evaluate antibody conjugation using isolated cell 
populations that express surface molecules of interest, and the assay is unique in its capacity to 
determine whether excess antibodies are present in GNR solutions. 
 We observed that excess antibodies were present in the supernatant of our Ab-GNR 
solutions, which were provided by a commercial vendor. This suggests that well-established 
antibody conjugation protocols may require the addition of fewer antibodies. It may also mean 
that antibodies are freed from GNRs during the centrifugation step, which could potentially make 
them less effective for tissue targeting.  
 Excess antibodies may pose a significant problem in-vivo, as they will compete for 
binding sites with Ab-GNRs. Hence, a larger dose of Ab-GNRs would be required to compete, 
an this could induce unwanted biological effects.  
 One limitation to this study is that Ab-GNRs are lost during centrifugation because they 
have a tendency to stick to containers they are centrifuged in. This is a common problem with 
Ab-GNRs, since washing to remove excess antibodies strips the GNRs of their polymer coatings 
allowing them to readily adhere to each other or to walls of the containers they are washed in.  
 Given that the number of wash cycles Ab-GNRs will survive is limited, our assay may be 
able to provide a method for checking Ab-GNR solutions prior to wash so that an optimal 
number of antibodies can be adsorbed to the surface while leaving few excess antibodies in 
solution. 
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3.3 SUMMARY AND DISCUSSION: GOLD NANORODS  
The GNR synthesis approach together with the in-vitro flow cytometry-based Ab-GNR assay 
presented in this chapter provide fundamental resources for evaluating the success of cellular 
targeting using GNRs. The flow cytometry assay provides a readily accessible technique for 
identifying whether antibodies are conjugated to GNRs and are targeting structures of interest. 
This approach should be applicable to multiple combinations of Ab-GNRs and isolated cell 
populations of interest. It may assist with optimizing the administered dosage of GNRs such that 
the maximum number of nanoparticles can be applied with a minimum number of excess 
antibodies.   
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4.0  PRE-CLINICAL STUDIES: IN-VIVO AND BIOCOMPATIBILITY EXPERIMENTS  
4.1 GOLD NANOROD INJECTIONS 
Few studies evaluating gold nanoparticles in the eye have been conducted,135-137 and to our 
knowledge, none have observed the behavior of GNRs after introduction to the eye. As 
demonstrated in Figure 15, GNRs cause an increase in backscattered signal that can be detected 
by SD-OCT. Given their potential to target low-backscattering structures such as RGCs, the 
presence of GNRs at the level of RGCs may provide a way to distinguish them from surrounding 
tissue.  
The goal of this study was to image GNRs in the eye in-vivo using a SD-OCT system, 
and to use SD-OCT and TEM imaging to document the distribution of particles in the posterior 
segment after injection.  
4.1.1 Animals and Methodology 
Healthy adult male C57Bl/6 mice (Jackson Laboratory, Bar Harbor, ME) were used in this study. 
Mice were maintained in the University of Pittsburgh Animal Facility with a 12-hour light/dark 
cycle and had free access to water and standard laboratory feed. This experiment met the 
approval of the University of Pittsburgh’s Institutional Animal Care and Use Committee and 
adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.  
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Injection of GNRs 
Animals were anesthetized with an intraperitoneal injection of ketamine (Ketaject, 
Phoenix Pharmaceuticals, St. Joseph, MI; 80 mg/kg) and xylazine (Xyla-ject, Phoenix 
Pharmaceuticals, St. Joseph, MI; 5 mg/kg) before the injection of GNR. The eye was proptosed 
with forceps and an incision was made at the limbus by the insertion of a 30-gauge needle. A 33-
gauge hypodermic needle fitted on a Hamilton 700 series microsyringe (Hamilton Co, Reno, 
NV) was then inserted into the incision site. This was used to administer a 2µl intravitreal 
injection of either GNR (51mg/ml) or phosphate buffered saline (PBS; sham injection). The 
procedure was performed under a surgical microscope in one eye per animal. 
 
OCT Imaging 
 Animals were anesthetized, as described above, in order to prevent large movements 
during OCT scanning. Tropicamide (1%; Falcon Pharmaceuticals, Fort Worth, TX) was applied 
topically to each eye for pupil dilation. Hydroxymethylcellulose ophthalmic demulcent solution 
(Goniosol 2.5%; Akon, Buffalo Grove, IL) was used to preserve corneal hydration and couple a 
thin glass cover slip to the cornea to neutralize corneal optical power and enable focusing of the 
OCT imaging beam on the retina. Mice were secured on a custom stage, which allowed for free 
rotation so images of specific landmarks, such as the optic nerve head, could be acquired. Scans 
of the retina, vitreous and posterior lens were acquired (1.5 x 1.5 x 2 mm scan at surface of cover 
slip, 250x250x1024 pixels, four consecutively-repeated axial scans at each sampling location; 
Bioptigen, Research Triangle Park, NC). Baseline images were acquired prior to intravitreal 
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injections. Follow-up images were acquired 24 hours after the injection using identical scan 
settings. 
 
Transmission Electron Microscopy 
At the end of this experiment, the mice were sacrificed by inhalation of CO2 and eyes 
enucleated and immersion fixed in 2.5% glutaraldehyde overnight at 4oC for transmission 
electron microscopy (TEM). Following fixation, the posterior lens and vitreous were dissected 
out and this tissue was washed 3 times in PBS, then post-fixed in aqueous 1% OsO4, 1% 
K3Fe(CN)6 for 1 hour. Following 3 PBS washes, the tissue was dehydrated through a graded 
series of 30-100% ethanol, 100% propylene oxide then infiltrated in 1:1 mixture of propylene 
oxide:Polybed 812 epoxy resin (Polysciences, Warrington, PA) for 1 hr. After several changes of 
100% resin over 24 hrs, the pellet was embedded in molds, and cured at 37oC overnight. This 
was followed by an additional hardening at 65oC for two more days. Ultrathin (60 nm) sections 
of the vitreous and lens were collected on copper grids, stained with 2% uranyl acetate in 50% 
methanol for 10 minutes, followed by 1% lead citrate for 7 min. Sections were imaged using a 
JEOL JEM 1210 transmission electron microscope (Peabody, MA) at 80 kV fitted with a side-
mount AMT 2k digital camera (Advanced Microscopy Techniques, Danvers, MA). 
4.1.2 Results 
A total of 12 mice, aged 19.4 ± 6.8 weeks, were used in this experiment: four eyes from four 
mice received a sham (PBS) injection and eight eyes from eight mice received a GNR injection. 
No systemic adverse effects were noted in any of the mice, however retinal edema was seen in 
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six eyes 1 day post-injection (1 sham, 5 GNR) and one eye showed a localized vitreous 
hemorrhage.  
OCT imaging showed a slight change in intensity in sham-injected eyes, while the GNR-
injected eyes showed a marked increase in OCT signal. Pre- and post-injection images from two 
mice are shown in Figure 21. The sham injection caused what appeared to be a mild 
inflammatory reaction as evident by the appearance of small, round focal areas of scattering in 
the vitreous. GNRs appear to be decorating the vitreous, anterior hyaloid membrane and 
posterior surface of the lens with marked enhancement of the OCT signal. Signal enhancement in 
the vitreous and near the posterior capsule of the lens was evident when compared to the pre-
injection image and to the sham injection. The strong signal from the vitreous caused attenuation 
of the retinal signal. A similar vitreous signal enhancement was observed in all GNR-injected 
eyes. An additional mouse was imaged out to 30 days post-injection, and there remained a strong 
backscattering response from the vitreous (Figure 22). TEM confirmed the presence of GNRs in 
the vitreous and lining the posterior capsule of the lens (Figure 23). Very few GNRs were seen in 
the retina, and were concentrated in microglial cells (Figure 24). 
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Figure 21. Baseline and follow-up (1 day after injection) images from mice injected with sham and gold 
nanorods (GNR). Marked signal enhancement is observed in the GNR injected vitreous as compared to both pre-
injection and the sham injection images. The retinal signal is attenuated in the GNR-injected eye due to a shadowing 
effect caused by the strong backscattering signal from the vitreous. Abbreviations: L – Lens, V – Vitreous, R – 
Retina, ON – Optic Nerve, HC – Hyaloid Canal. 
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Figure 22. Baseline and follow-up (up to 30 days after injection) images from mice injected with gold 
nanorods (GNR). 
 
 
Figure 23. Transmission electron micrograph showing GNR in vitreous and lining the lens capsule after 
injection. 
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Figure 24. Transmission electron micrographs showing GNRs in microglia in the retina after injection. 
RPE – retinal pigment epithelium, PR IS – photoreceptor inner segment, ONL – outer nuclear layer, OPL – outer 
plexiform layer, INL – inner nuclear layer 
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4.1.3 Injection Summary and Discussion 
In this study, we used GNRs developed in Section 3.1 and observed that, when injected into 
mouse eyes, the GNRs caused a substantial increase in OCT signal in the vitreous for up to 30 
days after injection. While previous studies have suggested that gold nanoparticles can enhance 
backscattering in-vitro,56, 57, 59, 61, 63 and demonstrated in-vivo contrast-enhancing capabilities of 
nanoshells65, 138 and gold nanoparticles64 in the skin and mouth, respectively, to our knowledge 
this is the first study showing the contrast-enhancing ability of GNRs in the eye in-vivo. 
This experiment qualitatively compared cross-sectional scans from GNR and PBS 
injected eyes. We did not compare cross-sectional scans or individual axial scans because SD-
OCT exhibits a nonlinear intensity drop-off with depth.4 The ocular structures we imaged (lens, 
vitreous and retina) were not aligned in the axial direction pre- and post-injection since the 
volume of the vitreous change, and thus quantitative intra-scan comparisons of backscattered 
intensity values would not be appropriate. In addition, returning precisely to one scanning 
location before and after GNR injection is difficult since landmarks such as blood vessels may be 
obscured by GNRs in the vitreous and the position of the mouse may be slightly different from 
scan to scan due to the angle of rotation of the eye with respect to the OCT beam.  
As shown in the TEM image of Figure 13b, our method of GNR synthesis produced a 
distribution of sizes. While the majority of the solution consisted of GNRs, some spherical 
artifacts were present in the injected solution. Although we observed a substantial increase in 
signal in the vitreous of mice in this experiment, it may be possible to use a lower-dose injection 
of more uniformly-shaped GNRs to cause a similar increase in signal. 
While the presence of GNRs in the vitreous was confirmed using TEM, it is also possible 
that inflammatory cells contributed to some of the increase in vitreous reflectance as we 
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observed what appeared to be a small inflammatory reaction with the sham injection that caused 
a mild signal increase. Although the whole eye remained structurally intact after the injection of 
GNRs, and all animals survived the injection, future studies are necessary to determine whether 
there is cytotoxicity or if any functional deficits develop related to the GNRs. The increased 
number of mice with retinal edema with the GNR injection as compared to sham injection may 
indicate inflammation or toxicity or may be the result of complications from the injection. An 
investigation into whether an inflammatory response is present after injection is reported in 
Section 4.2. In summary, we present a novel in-vivo signal-enhancing method using GNRs to 
highlight vitreous structures in OCT images.   
4.2 BIOCOMPATIBILITY EXPERIMENTS 
Nanoparticles are receiving increased attention in ophthalmology for their potential as molecular 
contrast and therapeutic agents for optical imaging and vehicles for drug delivery.139 Metallic 
nanoparticles, such as gold nanoparticles and gold nanorods (GNRs) may be particularly useful 
for optical imaging given their localized surface plasmon response (SPR), which facilitates 
strong scattering and absorption of light.20, 21 
Very little is known about the behavior of gold nanoparticles in the eye. One group 
injected gold nanoparticles intravenously into mice and showed that 20 nm diameter colloidal 
gold nanoparticles could pass through the blood retina barrier and enter the retina while 100 nm 
particles could not.135 They found that the presence of the 20 nm particles did not cause 
apoptosis in retinal neurons, endothelial cells or glial cells. A second group investigated the use 
of antibody-conjugated gold nanoparticles injected subretinally and showed they were still 
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present in the retina and retinal pigment epithelium at 3 months post-injection.137 A third study 
used gold nanoparticles injected into the vitreous of Dutch-belted rabbits and looked by light 
microscopy.136 They observed cellular atrophy within the retina but did not observe 
inflammation 15 and 29 days after the injection. However, since they did not look for 
inflammation at earlier time points it is unclear whether the nanoparticles caused atrophy. 
One critical step in establishing the utility of gold nanoparticles in general and GNRs in 
particular is the assessment of biocompatibility after introduction into the eye. Studies involving 
gold nanoparticles are inconsistent with respect to establishing a clear understanding of their 
biocompatibility. Some gold nanoparticles have been shown to be nontoxic,71, 140 while others 
have been shown to be toxic depending on size, shape or surface chemical characteristics.141-144 
There is evidence that the presence of gold nanoparticles can elicit an undesired immune 
response.51 GNRs may be taken up by macrophages with higher efficiency than spherical gold 
nanoparticles depending on their surface chemistry.145 This may be due to a similarity in shape to 
rod-like bacteria, which can be internalized in nonphagocytic cells.146 While many reported 
toxicology studies have been performed in-vitro, there is preliminary in-vivo evidence showing 
gold nanoparticles can cause inflammation.147   
To our knowledge, there have not been any reports on the biocompatibility of GNRs 
introduced into the eye. As a first step to determining whether GNRs may be able to be used in 
the eye, it is important to characterize the immunogenic response. The goal of this study, 
therefore, was to determine whether GNRs elicit an inflammatory response after injection into 
the vitreous of mice.  
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4.2.1 Methodology 
Healthy adult male C57Bl/6 mice (Jackson Laboratory, Bar Harbor, ME) were used in this study. 
Mice were maintained in the University of Pittsburgh Animal Facility with a 12-hour light/dark 
cycle and free access to water and standard laboratory feed.  
 
Gold Nanorods 
The nanoparticles used in this experiment were obtained from Nanorods, Inc 
(Germantown, MD), and were either coated with antibodies (α-CD90.2) or polystrene sulfate 
(PSS) using a well-established method for antibody conjugation published by Huang et al128 and 
described in detail in Section 3.3.1. CD90 is a molecule expressed on the surface of retinal 
ganglion cells and T-cells, and PSS is a detergent used to detoxify the GNRs by displacing cetyl 
trimethylammonium bromide (CTAB). CTAB is a cytotoxic surfactant that is present during the 
seed-mediated, surfactant directed synthesis of the GNRs.122 PSS also serves to prevent clumping 
of nanorods in solution. Both the Ab-GNR and PSS-GNR solutions had an optical density (OD) 
of 50.  
 
Sterility Monitoring  
Prior to injection of the GNRs, we ruled out the possibility of bacterial contamination of 
the GNR solutions by culturing a sample on standard Chocolate II Agar Medium with 
Hemoglobin and Isovitalex (BD Diagnostic Systems, Sparks, MD) by streaking 1 µl using a 
calibrated loop. The agar plates were incubated at 36 oC under 6 % CO2 at atmospheric 
conditions and monitored for 3 days for bacterial growth.  
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Injections 
Animals were anesthetized with an intraperitoneal injection of ketamine (Ketaject, 
Phoenix Pharmaceuticals, St. Joseph, MI; 80 mg/kg) and xylazine (Xyla-ject, Phoenix 
Pharmaceuticals, St. Joseph, MI; 5 mg/kg) prior to the injection. The eye was proptosed using 
forceps and an incision was made at the limbus by the insertion of a 30-gauge needle. A 33-
gauge hypodermic needle fitted on a Hamilton 700 series microsyringe (Hamilton Co, Reno, 
NV) was then inserted into the incision site to administer a 2 µl intravitreal injection. The 
procedure was performed under a surgical microscope in both eyes per animal. There were four 
experimental groups included in this study, as summarized in Table 2. 
Table 2. Experimental groups; OD – optical density, λspr – surface plasmon resonant wavelength 
Group Description of Injection 
1 No injection  
2 Phosphate buffered saline; Sham injection  
3 Polystyrene sulfate conjugated gold nanorods; OD = 50, λspr = 850 nm 
4 Antibody conjugated gold nanorods (α-CD90.1 antibodies); OD = 50, λspr = 857 nm 
 
Transmission electron microscopy 
A subset of mice was euthanized by inhalation of CO2 at 24 hours post-injection. These 
mice received an injection in one eye, and only the test eye was processed for TEM. Eyes were 
enucleated and immersion fixed in 2.5% glutaraldehyde overnight at 4oC for TEM. Following 
fixation, the posterior lens and vitreous were dissected out and this tissue was washed and then 
post-fixed in aqueous 1% OsO4, 1% K3Fe(CN)6. The tissue was dehydrated and then infiltrated 
in 1:1 mixture of propylene oxide:Polybed 812 epoxy resin (Polysciences, Warrington, PA). The 
pellet was embedded in molds and hardened and ultrathin (60 nm) sections of the vitreous and 
lens were collected on copper grids and stained. Sections were imaged using a JEOL JEM 1210 
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transmission electron microscope (Peabody, MA) at 80 kV fitted with a side-mount AMT 2k 
digital camera (Advanced Microscopy Techniques, Danvers, MA). 
 
Collagenase digestion of eyes for flow cytometry 
The remaining mice were euthanized by inhalation of CO2 and their eyes enucleated and 
processed for flow cytometry. Each eye was immediately washed in PBS to remove any excess 
blood resulting from the enucleation, then transferred into a 2 ml collagenase IV digest solution 
consisting of 1 mg/ml collagenase IV (Sigma, St. Louis, MO) 0.25 mg/ml Deoxyribonuclease I 
(Sigma) and 1% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA) in RPMI 
1640 media (Mediatech, Inc, Manassas, VA). Eyes were gently chopped with scissors to increase 
surface area for digestion, and placed in the collagenase IV digest solution for 1.5 hours, with the 
solution resuspended after 45 min to ensure a thorough digestion. 
After digestion, each eye solution was filtered through a nylon screen (70 µm), washed 
with PBS and then resuspended in 400 µl FACS buffer (PBS + 1% FBS). One-quarter of each 
eye solution (100 µl) was added to an individual well of a 96 well plate and then samples were 
incubated with unconjugated anti-CD16/CD32 antibodies (BD Pharmingen, San Diego, CA) for 
10 minutes on ice in the dark to block Fc receptors. Wells were then washed with FACS buffer, 
and stained with a mix of antibodies (Table 3) for 20 min on ice in the dark. Pooled eye samples 
spiked with Thy1.2+ E.G7-OVA tumor cells were stained individually with Thy1.2 FITC, 
Thy1.2 PE, CD45 PerCP, Thy1.2 APC, or CD11b Pac Blue as single color controls to set flow 
cytometry compensation. 
Isotype controls were also set using this pooled sample by staining with CD45 PerCP, 
Rat IgG2aκ PE, CD11b Pacific Blue, Rat IgG2bκ FITC, Rat IgG2bκ APC. A pacific orange 
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viability probe was added along with CountBright Absolute Counting Beads (Invitrogen, 
Camarillo, CA) to determine the absolute number of cells of respective immune cell populations 
and analysis was performed using FlowJo software (Tree Star, Inc, Ashland, OR).  
Table 3. Fluorescent antibodies used for flow cytometric staining 
Antibody (Fluorescent Marker) Target 
αCD45 (PerCP) Leukocytes 
αThy1.2 (PE) T-cells, Neurons 
αCD11b (Pacific Blue) Myeloid cells 
αGR-1 (FITC) Neutrophils 
αF4-80 (APC) Macrophages 
Aqua Viability (Pacific Orange) Live/dead cell discrimination 
 
Statisical Analysis 
Generalized estimation equations were fitted to model the logarithm of cell counts for 
CD45+ leukocytes, Thy1.2+ T-cells, CD11b+ myeloid cells, CD11b+ F4/80+ GR-1- 
macrophages, and CD11b+ F4/80- GR-1+ neutrophils, taking into account clustering that 
occurred between eyes. This allowed us to compare control and GNR-injected eyes (Groups 1, 2, 
3 and 4) to evaluate differences in inflammatory cell numbers between groups.  An α-level of 
0.05 was used as a cutoff for statistical significance. 
4.2.2 Results 
A total of 26 eyes (14 mice, age 127 days) were included in this experiment. Two mice (2 eyes) 
received an Ab-GNR injection and were processed for TEM. Of the remaining 12 mice, three (6 
eyes) did not receive an injection, three (6 eyes) received PBS injections, three (6 eyes) PSS-
GNR injections and three (6 eyes) Ab-GNR injections. One PSS-GNR injection had a technical 
failure (inability to locate the incision site for injection), and this eye was excluded from the 
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study. In total, 23 eyes were processed for flow cytometry to obtain cell counts 24 hours post-
injection.  
Representative TEM images from 24 hours post Ab-GNR injection are shown in Figure 
25. After 24 hours, GNRs appear to be clustered extracellularly within strands of the vitreous, 
with many inflammatory cells in close proximity or surrounding and engulfing the nanoparticles. 
Some GNRs have been phagocytosed by these inflammatory cells. 
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Figure 25. TEM images from two mice (top and bottom panels) 24 hours post GNR injection. (Top left) 
Arrowheads show a line of extracellular particles near inflammatory cells and (Top right) arrows show some free 
particles as well as some that have been internalized. (Bottom left) Extracellular and intracellular GNRs are evident 
when looking at magnified section (Bottom right). The rectangles indicate the location of higher magnification 
images. 
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Mean cell counts are shown in Figure 26 and Table 4. In eyes that received no injection 
or a PBS injection (Groups 1 and 2), there were no statistically significant differences for any 
cell count except for F4-80-/GR-1+ neutrophil cells. Group 4 was statistically significantly 
different from Group 1 for all cell types, and Group 3 was statistically significantly different 
from Group 1 for all cell types except Thy1.2+ T-cells. The groups receiving GNR injections 
(Groups 3 and 4) were not statistically significantly different from each other for any cell count, 
but were statistically significantly different from the PBS-injection group (Group 2) for all 
counts except Thy1.2+ T-cells, where Groups 2 and 3 were not statistically significantly 
different. 
  69 
 
Figure 26. Flow cytometric analysis of collagenase-digested eyes after indicated treatments to determine 
the number of infiltrating CD45+  leukocytes (A.) that expressed Thy1.2 (B.), T cells, or CD11b (C.) myeloid cells. 
CD11b+ cells were further characterized for expression of F4/80 (D.) and GR-1 (E.) to identify F4/80+ GR-1- 
macrophages and F4/80- GR-1+ neutrophils.  
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Table 4. Expected cell counts and 95% confidence intervals from generalized estimation equation models of cell 
counts for (A) CD45+  leukocytes that expressed Thy1.2 (B), or CD11b (C), and CD11b+ cells that expressed F4/80 
(D) and GR-1 (E). P-values for pairwise comparison of groups for a given cell type are indicated at right, with 
statistically significant differences indicated by * 
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4.2.3 Summary and Discussion 
We observed an increase in the number of inflammatory cells 24 hours after intravitreal injection 
of both PSS-coated and antibody-coated GNRs as compared to sham or no intravitreal injection. 
Our TEM images demonstrate that free GNRs stay in the vitreous after 24 hours and there is an 
inflammatory infiltrate. There are several studies suggesting that interactions between gold 
nanoparticles and inflammatory cells cause recruitment and internalization of particles, and this 
is in line with what we observed.71, 148, 149 
The mechanism by which nanoparticles enter cells has been investigated. Some reports 
categorize the internalization of nanoparticles as receptor-mediated endocytosis150 via scavenger 
receptors.71 However, the exact mechanism is unclear given the limited techniques available for 
visualizing nanoparticles intracellularly.51 
While we did not observe a statistically significant difference in inflammation between 
eyes injected with GNR, either PSS-conjugated or Ab-conjugated, some studies have shown that 
surface modification can delay uptake of nanoparticles, which may account for the slight 
differences between those groups.145 The surface charge of nanoparticles can affect the extent of 
the inflammatory reaction, with cationic particles being more likely to induce inflammatory 
responses than anionic.51 Interestingly, the GNRs used in this experiment have a slightly 
negative charge. In addition, surface carboxy groups can induce mRNA expression of pro-
inflammatory genes. Conversely, amino groups appear to induce expression of anti-inflammatory 
proteins.145 In addition, small impurities within particles may make them unstable in physiologic 
conditions, thereby eliciting an immune response.51 
We have provided evidence that GNRs modified with PSS and conjugated with 
antibodies can elicit an immune response. PSS has been used as a detergent to detoxify 
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commercial products and is considered safe for in-vivo applications.151 One study, however, 
found that this is not the case and that PSS caused cytotoxicity in-vitro.152 Future studies 
investigating different surface coatings, such as polyethylene glycol (PEG) and polyethylene 
oxide (PEO), are required. Nanoparticles whose surfaces are not modified to prevent adsorption 
of blood serum proteins (opsonins), which signal cells to ingest the particles, have been reported 
to be readily removed from the bloodstream by macrophages.153 Modifying the surface using a 
polymer like PEG causes fewer proteins to bind,154 which may therefore reduce the extent of the 
immune response.  
The aspect ratio of the GNRs in this study was chosen to align with current commercial 
OCT devices, which have light sources with near-infrared wavelengths. However, it is also 
necessary to consider the surface characteristics and shape of nanoparticles when optimizing 
them for in-vivo applications. Diameter,155 shape156 and aspect ratio157 appear to affect the extent 
to which nanoparticles are phagocytosed. In addition, we administered a highly light-scattering 
dose of GNRs (OD=50), so it may be possible that a lower dose would elicit less of a response 
and therefore less internalization of particles.  
Based on their location within TEM images, the phagocytic cells we observed may be 
hyalocytes, which reside in the peripheral or cortical region of the vitreous body abutting the 
inner surface of the retina.158 These cells belong to the monocyte/macrophage lineage. 
Recently, a method for phagocytosis-independent extracellular removal of bacteria, 
neutrophil extracellular traps,159 was discovered and shown to occur in the clearance of 
nanoparticles.160 Granulocytes, monocytes and macrophages have form networks of traps that are 
comprised of DNA and protein.159 The bottom right image within Figure 25 shows a network of 
fibers in the vitreous, which resemble these extracellular traps. Future studies are necessary to 
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determine whether the components of these structures match those of the extracellular traps or 
are collagen fibers in the vitreous.  
In summary, our findings suggest that GNRs may elicit an immune response after 
intravitreal injection of GNRs in the mouse. This inflammatory response may present an obstacle 
in getting GNRs into the retina for use as contrast or therapeutic agents with optical imaging. 
Additional studies are required to determine whether GNR design modifications can minimize 
this inflammatory response.  
4.3 SUMMARY AND DISCUSSION: PRE-CLINICAL EXPERIMENTS 
In these experiments, we were able to image GNRs in-vivo in the eye for the first time and 
observed that many tend to remain present in the vitreous, altering backscattered intensity within 
SD-OCT images, after intravitreal administration. A higher frequency of edema associated with 
GNR injections indicated an inflammatory response might be occurring in parallel with the in-
vivo administration of GNRs. The presence of an inflammatory infiltrate was confirmed using 
collagenase digestion of whole eyes, and was present regardless of whether the GNRs were 
conjugated with antibodies.    
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5.0  DISSERTATION SYNOPSIS 
These experiments established the mouse eye as a practical platform for posterior segment 
contrast imaging studies with SD-OCT, as we were able to provide a reproducible method for 
automatically obtaining retinal thickness measurements in healthy mice. After successfully 
acquiring retinal thickness measurements in a cross-sectional study, we applied this technique to 
a longitudinal study monitoring a population of mice with experimental glaucoma. In quantifying 
retinal thickness changes from repetitive scanning, we were able to observe structural changes in 
a given eye over time. Retinal thickness initially increased rapidly and gradually decreased over 
the course of three weeks. This gradual thinning out to three weeks is in line with the literature 
on nerve crush injury, but we were the first to report an initial transient thickening. Our SD-OCT 
approach is a substantial improvement over conventional histology methods, which require 
sacrificing several mice at different time points in an attempt to extract a trend using multiple 
cross-sectional data. Not only does SD-OCT imaging enable true longitudinal analyses, it also 
substantially reduces the number of animals to be used in experiments.  
In parallel to developing a technique for imaging the mouse eye, we also designed a gold 
nanorod contrast agent that caused an enhancement in intensity of light backscattered from the 
solution as detected by SD-OCT. We then developed an assay that allowed us to characterize the 
bioconjugation of GNRs with fluorescently labeled antibodies, tumor cells and flow cytometry, 
and found that the presence of excess antibodies in Ab-GNR solutions is common. This suggests 
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that well-established antibody conjugation protocols will need to be adjusted before in-vivo 
applications, as excess antibodies in solution may compete for binding sites with Ab-GNRs. 
The results of our in-vivo injection experiments suggest that a considerable amount GNRs 
stay in the vitreous, line the posterior surface of the lens and stick to the hyaloid membrane of 
the mouse eye for several days following injection. We found that, while their presence increases 
the backscattered signal intensity in the vitreous – an otherwise clear media – the lingering of 
these highly reflective GNRs in the vitreous obscures the underlying retinal signal. TEM sections 
confirmed that GNRs stay in the vitreous and that very few particles enter the retina, with those 
that are in the retina consistently localized in microglial cells.     
TEM, together with our whole-eye collagenase digestion/flow cytometry assay, 
established that there is a significant inflammatory infiltrate 24 hours after injection of PSS-
GNRs and Ab-GNRs, and that there is not a significant difference in the inflammatory response 
between the two types of particles. The inflammatory cells may be presenting an obstacle, 
neutrophil extracellular traps, blocking GNRs from getting into the retina. In addition, they may 
not be able to easily pass through the ILM given their dimensions, surface coatings, or charge.  
5.1 LIMITATIONS 
While we have shown that GNRs resonant at 840-860 nm can cause backscatter changes 
detectable by SD-OCT in-vivo, there are some limitations associated with our experimental 
design. One problem we encountered when imaging the mouse eye is that mice develop a 
reversible cataract, which may be due to dehydration in response to systemic anesthesia and a 
corresponding decreased body temperature.97 While this can be somewhat alleviated by imaging 
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as close to administration of the anesthetics as possible, it limits the length of imaging sessions to 
~20 min. In an attempt to lengthen this window, we tried exposing the mice to different topical 
drops and heat, but were not able to prevent or delay the onset of cataract. Imaging an awake 
mouse may offer a solution. In these experiments, however, the time required to align and locate 
structures of interest, such as the ONH, prevented this. 
A limitation to imaging with mice on a movable stage is that the orientation of the mouse 
changes from scan to scan. We presented a way to manually register images, but a fully 
automated approach would be preferred, as it would minimize subjectivity and decrease 
processing time. Detection and alignment techniques based on blood vessel segmentation within 
OCT fundus images may improve this,100 but this registration method is not yet optimized for 
mouse images.  In addition, rotating and translating mice means that exact sectoral boundaries 
are unknown. Thus, when measuring thicknesses, we were limited to only large sectors 
(quadrants). In order to analyze smaller segments, such as clock hours, it would be necessary to 
know the exact position of every mouse eye with respect to the stage and SD-OCT system, 
which was not available in our set up. 
 In our nerve crush experiment, we observed a consistently higher rate of corneal scarring 
in eyes that were undergoing the procedure versus control eyes. This resulted in the exclusion of 
several images due to shadowing from the scar. We hypothesize that was caused by longer 
recovery time after surgery, or from mechanical damage during the surgical procedure. We tried 
to alleviate this by applying a topical ointment to eyes after surgery, and by taking care not to 
damage the cornea during the procedure, but scarring still occurred.  
Ideally, in our nerve crush experiments, we would have been able to directly measure 
RNFL thinning, as the RNFL is directly affected by the surgical injury. However, we were not 
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able to segment the RNFL since mice have a very thin layer and measurements are unreliable 
with our current algorithm. Additional A-scan averaging may improve RNFL algorithm 
performance, or segmentation of retinal regions that are more specific than TRT (eg, from the 
ILM to the inner plexiform/outer nuclear layer boundary) may be possible. 
Very few GNRs entered the retina after intravitreal injection and many were retained in 
the vitreous, causing an inflammatory reaction and blocking a substantial portion of the signal 
returning from the retina. Thus, we were not able to isolate RGCs within OCT cross-sections 
since they cannot reach and pass through the ILM. Other studies suggest that only smaller 
nanoparticles can enter the retina through the blood retina barrier,135 so it is unlikely that GNRs 
could be directed to RGCs using an intravenous injection. In addition, if Ab-GNRs were able to 
bind to target cells, we do not know the downstream signaling effects, or consequences of 
binding with respect to RGC function. Previous studies have shown that anti-Thy-1 binding can 
cause neurite outgrowth in dorsal root ganglion cells in-vitro,161 but the effect on RGCs in-vivo is 
unclear.   
We observed that GNRs elicit an inflammatory response after being introduced into the 
vitreous, which currently limits their use in-vivo. It is possible that a manufacturing detail, such 
as endotoxins evading detection in our sterility monitoring technique, the use of PSS, trace 
amounts of CTAB, or the charge of the particles is causing this response. Future work is 
necessary to reveal the cause of inflammation. 
While the scattering response attributed to GNRs observed in our SD-OCT systems was 
easy to discern compared to a low-scattering media, it may be difficult to isolate scattering 
nanoparticles within scattering tissue. However, since it is possible to access the spectral content 
of a backscattered interferometric OCT signal using SD-OCT detection, the depth-resolved 
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spectral characteristics of tissue components can be extracted in a technique referred to as 
spectroscopic OCT.2 GNR spectral signatures have been resolved using this technique.162 The 
potential utility of GNRs in spectroscopic OCT is described in the next section.  
5.2 FUTURE WORK 
While we developed a reproducible method for imaging mice, effort is required to determine 
how to image mice without damaging the cornea. In order to focus on the mouse retina, it is 
necessary to compensate for the steep curvature of the mouse cornea. This can be done using a 
flat coverslip or a contact lens with a flat surface. Initially, we used a coverslip and hypothesized 
that uneven pressure distribution was causing corneal defects. However, when we tried a custom-
made mouse contact lens in an attempt to distribute pressure evenly across the cornea, we still 
observed corneal scarring. Modifying the lenses used in the SD-OCT system sample path may 
eliminate this problem. 
Our nerve crush experiment provided a model for measuring thickness changes after 
injury, but may also be a model for an inflammatory reaction causing neuronal degeneration. 
Future investigation is required to characterize what is causing the early edema and whether this 
is causing neuronal degeneration. If an inflammatory infiltrate is the source, it may be possible to 
use anti-inflammatory agents early in the process to prevent or reduce cellular damage after 
nerve crush injury, thus providing a novel platform for testing pharmaceutical agents and 
interventions. We also observed that the contralateral eye of nerve-crushed mice appeared to be 
affected by the procedure (data not shown). If this is the case, experiments where the 
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contralateral eye is used as a control need to be reconsidered. Further studies are required to 
assess the extent of damage to the contralateral eye.  
We observed that GNRs did not readily enter the retina and that an inflammatory 
infiltrate is present after the introduction of GNRs into the eye. Surface modification of GNRs, 
with biocompatible polymers such as PEG, may improve biocompatibility and distribution in the 
eye, allowing for diffusion into the retina. It may be possible to use proportionally smaller gold 
nanorods, with the same aspect ratio – and therefore SPR wavelengths – to cause a considerable 
change in scattering while simultaneously allowing for better diffusion into tissue given the 
smaller size. Currently, however, the transverse dimension of the GNRs is governed by the seed 
particle size, which is fixed in the current wet chemical synthesis protocols.  
GNRs were highly scattering with respect to the vitreous body in SD-OCT images. 
However, although GNRs can be designed to have high backscattering cross-sections, many 
tissue structures, such as the RNFL, are inherently highly scattering. A large dose of 
nanoparticles may therefore be required to present enough contrast for distinguishing between 
structures of interest. Detecting changes in OCT signal based on absorption of light,163 as 
opposed to backscattering, or assessing spectroscopic characteristics attributed to GNRs162 may 
offer an alternative. Since gold nanorods have a well-established signature spectral response and 
will be present at different depths in tissues, it follows that it should also be possible to detect the 
presence of nanorods at different depths by assessing the spectral content of backscattered 
interferometric signals using spectroscopic OCT. 
One promising application of GNRs is in photoacoustic tomography (PAT) imaging.127 In 
PAT, images are formed by detecting ultrasonic waves that have been generated by irradiation 
with an optical source. PAT is highly sensitive to absorption, and Ab-GNRs have been used for 
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absorption-based targeted contrast enhancement in PAT.164 While PAT has only recently been 
applied to ophthalmology,165, 166 it is an emerging technique that may eventually be relevant to 
the diagnosis of ophthalmic diseases. 
5.3 CONCLUSIONS 
This dissertation developed the fundamental materials and provided the preliminary imaging data 
necessary to determine the utility of a targeted contrast agent for ophthalmic OCT imaging. We 
observed an increase in SD-OCT signal intensity in the vitreous after injection of GNRs, but very 
few GNRs were able to diffuse into the retina and an inflammatory response ensued. Our results 
indicate that the utility of GNR contrast agents administered intravitreally is limited.  
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APPENDIX A 
NANOROD DESIGN OPTIMIZATION 
The protocol presented by El-Sayed et al results in gold nanorods with a longitudinal resonance 
wavelength in the 700-750 nm range. Thus, to grow nanorods resonant in the 800-900 nm range, 
which corresponds to the wavelengths used in our OCT system, the following modifications 
were applied (Figure 27).  
 
Figure 27. Summary of steps taken to optimize GNR longitudinal resonant wavelength. A protocol by 
Nikoobakht and El-Sayed122 was modified by altering the [AgNO3] in the growth solution and adding acid according 
to the protocol by Prasad.167 
 
First, we optimized the [AgNO3] added to the growth solution. However, this 
modification allowed for growth of GNRs with a longitudinal resonance wavelength that was 
less than 800 nm (Figure 28).  
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Figure 28. Changing the molar concentration of AgNO3 that was added to the growth solution only 
allowed for a maximum longitudinal resonance wavelength of ~785 nm. 
 
Next, we added acid to the growth solution and allowed the solution to sit for 45 min at 
room temperature (Figure 29). This allowed for the growth of GNRs in the 800-900 nm range, 
and an example UV-Vis-NIR spectrum from a solution of particles can be seen in Figure 30. 
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Figure 29. The addition of acid to the growth solution allows for growth of GNRs resonant at ~850 nm 
 
 
Figure 30. UV-VIS-NIR spectrum of GNRs with longitudinal resonant wavelengths 820-850 nm, with 
ultrapurified MilliQ water shown for reference. OD – optical density. 
Our final protocol, listed in Section 3.1.1, took into account these optimization steps, with 
the exception that HCl was used in place of KCl to lower the pH of the solution.   
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Tomography. Investigative Ophthalmology and Visual Science. Accepted for publication. 
Gabriele ML, Wollstein G, Ishikawa H, Kagemann L, Xu J, Folio L, Schuman JS. History, 
current status and laboratory work for OCT. (Review) Investigative Ophthalmology and Visual 
Science. Accepted for publication. 
Gabriele ML, Ishikawa H, Schuman JS, Bilonick RA, Kim JS, Kagemann L, Wollstein G. 
Reproducibility of Spectral-Domain Optical Coherence Tomography Total Retinal Thickness 
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Schuman JS. Comparison of parameters from Heidelberg Retina Tomograph 2 and 3. 
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High Speed, Ultrahigh Resolution Optical Coherence Tomography High-Density Scanning. 
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